Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Evelo Therapeutics Opens Headquarters In Cambridge, Massachusetts

12/17/2015
Evelo Therapeutics, a biotech company pioneering the development of microbiome-based therapies for cancer, opened its new 9,000-square-foot headquarters at 620 Memorial Drive in Cambridge, Massachusetts.

"We are extremely pleased with our new facility and the opportunity that it affords Evelo during this important growth period," said Simba Gill, Ph.D., CEO of Evelo. "Cambridge is the undisputed hub of great biotech companies and we are excited to contribute to its legacy of innovative science and transformative medicine."

The new facility features state-of-the-art laboratory space and offices designed to foster collaboration. At this site, Evelo will continue to advance its research platform, based on a deep understanding of the cancer microbiome, and develop its Oncobiotic therapeutics as a new modality in cancer treatment, company officials said.

"We are pleased to celebrate the grand opening of Evelo's new headquarters in Cambridge," said Travis McCready, President/CEO of the Massachusetts Life Sciences Center, an investment agency that supports life sciences innovation, research, development and commercialization. "This new facility will allow the company to continue to grow and make important contributions to cancer therapeutics, one of the core strengths of our Commonwealth's life sciences ecosystem."

"We congratulate MassBio member Evelo Therapeutics on the grand opening of their exciting new headquarters in Cambridge, MA," said Robert K. Coughlin, President/CEO of MassBio. "We are thrilled to see Evelo Therapeutics' growth and know they will continue to thrive in Massachusetts' robust oncology research and development community."

Exclusive Research